VFA
ACHN

Virtus Fund Advisers’s Achillion Pharmaceuticals ACHN Stock Holding History

Virtus Fund Advisers’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$349K Buy
+121,264
New +$441K ﹤0.01% 406
2014
Q3 		– Sell
-8,260
Closed -$63K – 2250
2014
Q2 		$63K Buy
+8,260
New +$33K ﹤0.01% 1715

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtus Fund Advisers's ACHN Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Achillion Pharmaceuticals (ACHN) in Q4 2017: 121,264 shares worth $349K. The stake represents ﹤0.01% of the portfolio and ranks #406 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in ACHN as recently as Q2 2014.

Virtus Fund Advisers first reported a position in ACHN in Q2 2014 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold ACHN as of Q4 2017.

  • Virtus Fund Advisers held 121,264 shares of Achillion Pharmaceuticals worth $349K as of Q4 2017.
  • Achillion Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
  • Achillion Pharmaceuticals made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #406 holding.
  • Virtus Fund Advisers first reported a position in Achillion Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.